| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 170 | 324 | 1.795 | 3.709 | 3.940 | 4.959 | 5.382 | 5.750 | 3.999 | 1.602 |
| Total Income - EUR | 170 | 324 | 1.795 | 2.950 | 3.940 | 4.960 | 5.741 | 5.753 | 4.000 | 1.602 |
| Total Expenses - EUR | 3.516 | 4.494 | 3.394 | 5.368 | 2.279 | 13.931 | 8.132 | 7.516 | 7.600 | 5.071 |
| Gross Profit/Loss - EUR | -3.346 | -4.170 | -1.598 | -2.418 | 1.662 | -8.971 | -2.391 | -1.763 | -3.600 | -3.470 |
| Net Profit/Loss - EUR | -3.352 | -4.185 | -1.614 | -2.460 | 1.622 | -9.117 | -2.554 | -1.944 | -3.600 | -3.470 |
| Employees | 3 | 1 | 2 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Pharmingenia Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 621 | 331 | 332 | 0 | 0 |
| Current Assets | 8.206 | 6.291 | 8.546 | 6.676 | 13.522 | 6.481 | 4.136 | 2.963 | 3.041 | 3.007 |
| Inventories | 6.288 | 4.367 | 4.293 | 3.456 | 8.024 | 0 | 0 | 0 | 0 | 89 |
| Receivables | 1.882 | 1.885 | 3.906 | 1.751 | 2.711 | 2.757 | 2.144 | 2.142 | 2.406 | 2.639 |
| Cash | 36 | 39 | 346 | 1.469 | 2.786 | 3.724 | 1.992 | 821 | 635 | 279 |
| Shareholders Funds | -12.016 | -16.079 | -17.421 | -19.562 | -17.560 | -26.345 | -28.314 | -30.346 | -33.854 | -37.134 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 20.222 | 22.371 | 25.967 | 26.237 | 31.082 | 33.447 | 32.781 | 33.640 | 36.895 | 40.142 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4791 - 4791" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Pharmingenia Srl